These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 33704001

  • 21. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT, Wolff RF, Pouwels X, Oosterhoff M, Van Giessen A, Worthy G, Noake C, Armstrong N, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [Abstract] [Full Text] [Related]

  • 22. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy.
    Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, Dierssen-Sotos T, Gonzalez-Lopez MA, Gonzalez-Vela MC, Blanco R, Hernández JL, Llorca J, Gonzalez-Gay MA.
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1995-2001. PubMed ID: 25823684
    [Abstract] [Full Text] [Related]

  • 23. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
    Núñez M, Huete T, de la Cueva P, Sacristán JA, Hartz S, Dilla T.
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
    [Abstract] [Full Text] [Related]

  • 24. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C, Beauchet A, Burztejn AC, Severino-Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj-Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour JP, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse AC, Kupfer-Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles-Tsimaratos N, Mery-Brossard L, Pallure V, Lons-Danic D, Bouilly-Auvray D, Beylot-Barry M, Puzenat E, Aubin F, Mahé E, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie.
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O, Rodríguez-Soria VJ, Romero-Jiménez RM, Suárez R.
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [Abstract] [Full Text] [Related]

  • 27. Effect of treatment with methotrexate and coal tar on adipokine levels and indices of insulin resistance and sensitivity in patients with psoriasis vulgaris.
    Rajappa M, Rathika S, Munisamy M, Chandrashekar L, Thappa DM.
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):69-76. PubMed ID: 24665910
    [Abstract] [Full Text] [Related]

  • 28. The Safety Profiles of Adalimumab, Infliximab, Etanercept, Secukinumab and Ustekinumab in Psoriasis - A 30-month Observational Cohort Prospective Study of Adverse Events in Biologic Therapy.
    Paluch Z, Marques E, Boháč P, Zemková K, Hercogová J.
    Acta Dermatovenerol Croat; 2024 Mar; 32(1):7-16. PubMed ID: 38946182
    [Abstract] [Full Text] [Related]

  • 29. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
    Jemec GB, Ibler KS.
    J Drugs Dermatol; 2012 Aug; 11(8):939-42. PubMed ID: 22859238
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio-markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles.
    Hoffmann JHO, Knoop C, Schäkel K, Enk AH, Hadaschik EN.
    Acta Derm Venereol; 2021 May 25; 101(5):adv00462. PubMed ID: 33903917
    [Abstract] [Full Text] [Related]

  • 31. Biologic drug survival in Israeli psoriasis patients.
    Shalom G, Cohen AD, Ziv M, Eran CB, Feldhamer I, Freud T, Berman E, Oren S, Hodak E, Pavlovsky L.
    J Am Acad Dermatol; 2017 Apr 25; 76(4):662-669.e1. PubMed ID: 28038888
    [Abstract] [Full Text] [Related]

  • 32. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
    Sorensen EP, Fanucci KA, Saraiya A, Volf E, Au SC, Argobi Y, Mansfield R, Gottlieb AB.
    J Drugs Dermatol; 2015 Aug 25; 14(8):893-8. PubMed ID: 26267736
    [Abstract] [Full Text] [Related]

  • 33. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.
    Bissonnette R, Maari C, Barber K, Lynde CW, Vender R.
    J Eur Acad Dermatol Venereol; 2015 Aug 25; 29(8):1576-81. PubMed ID: 25600828
    [Abstract] [Full Text] [Related]

  • 34. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N, Nour T.
    Expert Opin Biol Ther; 2014 Jun 25; 14(6):749-56. PubMed ID: 24661040
    [Abstract] [Full Text] [Related]

  • 35. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre.
    Fotiadou C, Lazaridou E, Sotiriou E, Kyrgidis A, Apalla Z, Ioannides D.
    J Eur Acad Dermatol Venereol; 2016 Dec 25; 30(12):2091-2096. PubMed ID: 27406435
    [Abstract] [Full Text] [Related]

  • 36. Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study.
    Svedbom A, Wennerström C, Hjelm F, Tjärnlund A, Ståhle M.
    J Dermatolog Treat; 2024 Dec 25; 35(1):2398170. PubMed ID: 39229963
    [Abstract] [Full Text] [Related]

  • 37. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
    Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A.
    JAMA; 2011 Aug 24; 306(8):864-71. PubMed ID: 21862748
    [Abstract] [Full Text] [Related]

  • 38. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
    Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C.
    Health Technol Assess; 2017 Nov 24; 21(64):1-244. PubMed ID: 29105621
    [Abstract] [Full Text] [Related]

  • 39. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C, Creighton-Smith M, Sorensen EP, Dumont N, Gottlieb AB.
    J Drugs Dermatol; 2015 Aug 24; 14(8):881-6. PubMed ID: 26267734
    [Abstract] [Full Text] [Related]

  • 40. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.
    Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G.
    Br J Dermatol; 2013 May 24; 168(5):1124-7. PubMed ID: 23320916
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.